Praxis Precision Medicines, Inc. Common Stock PRAX
i
Market datapartial · fetched 2026-11-13T18:50:57.192Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-13T18:50:28.664664985Z
FundamentalsAlpha Vantage · unavailable
Praxis Precision Medicines, Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 292.25 | 101.3% | 12.0% | |||
| 25Δ | 351.52 | 73.9% | 9.3% | 300.36 | 93.3% | 9.9% |
| 30Δ | 346.23 | 74.0% | 8.1% | 308.48 | 85.3% | 7.8% |
| 35Δ | 341.21 | 73.9% | 7.0% | 314.16 | 80.6% | 6.4% |
| 40Δ | 336.60 | 73.2% | 6.0% | 319.28 | 76.7% | 5.3% |
| 45Δ | 332.12 | 72.3% | 5.1% | 323.60 | 74.6% | 4.5% |
| 50Δ | 327.85 | 71.9% | 4.3% | 327.78 | 72.7% | 3.7% |
| 55Δ | 323.76 | 72.0% | 3.7% | 332.51 | 74.3% | 3.2% |
| 60Δ | 319.66 | 72.0% | 3.1% | 337.85 | 80.0% | 2.9% |
| 65Δ | 315.54 | 71.1% | 2.6% | 343.20 | 82.2% | 2.5% |
| 70Δ | 311.43 | 70.3% | 2.0% | 348.55 | 81.9% | 2.0% |
| 75Δ | 306.83 | 69.9% | 1.6% | 354.78 | 82.2% | 1.5% |
| 80Δ | 301.99 | 69.7% | 1.2% | 361.92 | 83.0% | 1.1% |
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 292.25
- IV
- 101.3%
- B/E move
- 12.0%
25Δ
- Pseudo strike
- 351.52
- IV
- 73.9%
- B/E move
- 9.3%
- Pseudo strike
- 300.36
- IV
- 93.3%
- B/E move
- 9.9%
30Δ
- Pseudo strike
- 346.23
- IV
- 74.0%
- B/E move
- 8.1%
- Pseudo strike
- 308.48
- IV
- 85.3%
- B/E move
- 7.8%
35Δ
- Pseudo strike
- 341.21
- IV
- 73.9%
- B/E move
- 7.0%
- Pseudo strike
- 314.16
- IV
- 80.6%
- B/E move
- 6.4%
40Δ
- Pseudo strike
- 336.60
- IV
- 73.2%
- B/E move
- 6.0%
- Pseudo strike
- 319.28
- IV
- 76.7%
- B/E move
- 5.3%
45Δ
- Pseudo strike
- 332.12
- IV
- 72.3%
- B/E move
- 5.1%
- Pseudo strike
- 323.60
- IV
- 74.6%
- B/E move
- 4.5%
50Δ
- Pseudo strike
- 327.85
- IV
- 71.9%
- B/E move
- 4.3%
- Pseudo strike
- 327.78
- IV
- 72.7%
- B/E move
- 3.7%
55Δ
- Pseudo strike
- 323.76
- IV
- 72.0%
- B/E move
- 3.7%
- Pseudo strike
- 332.51
- IV
- 74.3%
- B/E move
- 3.2%
60Δ
- Pseudo strike
- 319.66
- IV
- 72.0%
- B/E move
- 3.1%
- Pseudo strike
- 337.85
- IV
- 80.0%
- B/E move
- 2.9%
65Δ
- Pseudo strike
- 315.54
- IV
- 71.1%
- B/E move
- 2.6%
- Pseudo strike
- 343.20
- IV
- 82.2%
- B/E move
- 2.5%
70Δ
- Pseudo strike
- 311.43
- IV
- 70.3%
- B/E move
- 2.0%
- Pseudo strike
- 348.55
- IV
- 81.9%
- B/E move
- 2.0%
75Δ
- Pseudo strike
- 306.83
- IV
- 69.9%
- B/E move
- 1.6%
- Pseudo strike
- 354.78
- IV
- 82.2%
- B/E move
- 1.5%
80Δ
- Pseudo strike
- 301.99
- IV
- 69.7%
- B/E move
- 1.2%
- Pseudo strike
- 361.92
- IV
- 83.0%
- B/E move
- 1.1%
Options history
Table
| Date | IV (%) |
|---|---|
| 88.97% | |
| 91.22% | |
| 90.65% | |
| 91.39% | |
| 92.32% | |
| 94.63% | |
| 94.60% | |
| 95.30% | |
| 94.70% | |
| 96.53% |
Biotechnology
PRLD
Prelude Therapeutics Incorporated, a precision clinical-stage oncology company, focuses on the discovery and development of small molecule therapies optimized to target key…
More →PRME
Prime Medicine, Inc. is a pioneering biotechnology company specializing in genetic medicine through its proprietary Prime Editing technology, which enables precise DNA…
More →PROK
ProKidney Corporation. The company is headquartered in Winston-Salem, North Carolina.
More →PRQR
ProQR Therapeutics NV, a biopharmaceutical company, is dedicated to the discovery and development of RNA-based therapies for the treatment of genetic disorders. The company is…
More →PRTA
Description unavailable
More →PTCT
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for patients with rare disorders. The company is…
More →